Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: A randomized clinical trial.
Jiangyuan Zhou, Yuru Lan, Tong Qiu...
https://pubmed.ncbi.nlm.nih.gov/40107509/Actively Recruiting
Led by West China Hospital · Updated on 2026-09-25
120
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are studying kaposiform hemangioendothelioma KHE, a rare vascular tumor, to evaluate different strategies for stopping the drug sirolimus, which has shown effectiveness in treating KHE but often leads to tumor regrowth after stopping. This phase 2 randomized trial aims to find the best way to discontinue sirolimus to reduce rebound growth. The study is sponsored by West China Hospital and focuses on treatment methods. Participants receive sirolimus under two different plans one group gradually stops the drug over two months, while the other follows a schedule of taking sirolimus three days per week and resting four days per week for six months, then tapering off over two months. These strategies are compared to see which reduces tumor regrowth best. During the study, participants are monitored for tumor rebound over 12 months using clinical or imaging assessments. Researchers also track disease complications and any side effects throughout the year. Participants or their guardians provide informed consent, and their blood and liverkidney function are checked to ensure safety during treatment. The study runs from 2025 to 2028 and uses a single-blind design.
CONDITIONS
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Y
Yi Ji, PhD
J
Jiangyuan Zhou, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 months
Participants receive sirolimus following one of two stopping schedules: a gradual two-month taper or a six-month intermittent dose followed by tapering.
Regular visits during treatment and tapering
Duration - 12 months
Participants are monitored for 12 months to assess tumor regrowth, disease complications, and any side effects after stopping sirolimus.
Scheduled monitoring visits
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jiangyuan Zhou, Yuru Lan, Tong Qiu...
https://pubmed.ncbi.nlm.nih.gov/40107509/Jiangyuan Zhou, Kaiying Yang, Shiyi Dai...
https://pubmed.ncbi.nlm.nih.gov/34273457/Jiangyuan Zhou, Yanan Li, Tong Qiu...
https://pubmed.ncbi.nlm.nih.gov/36916140/Jiangyuan Zhou, Tong Qiu, Zixin Zhang...
https://pubmed.ncbi.nlm.nih.gov/39831682/Yi Ji, Siyuan Chen, Jiangyuan Zhou...
https://pubmed.ncbi.nlm.nih.gov/35030255/West China Hospital
Lead Sponsor